IMMUNITYBIO, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
IMMUNITYBIO, INC. (IBRX) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$11.62 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2019-11-05
- IMMUNITYBIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2019-09-30 was $843.00K, a 93.99% decline year-over-year.
- IMMUNITYBIO, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2018-09-30 was $14.02M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month |
|---|---|---|---|
| 2019-09-30 | $843.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$11.62M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | -$12.46M 10-Q · filed 2019-08-06 | ||
| 2018-09-30 | $14.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $14.62M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $603.00K 10-Q · filed 2019-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |